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Abstract 
Background: Comorbidity is increasingly common in kidney transplant recipients, yet the 
implications for transplant outcomes are not fully understood. We analysed the relationship 
between recipient comorbidity and survival outcomes in a UK-wide prospective cohort study – 
ATTOM. 
Methods: 2100 adult kidney transplant recipients were recruited from all 23 UK transplant 
centers between 2011-2013. Data on 15 comorbidities were collected at the time of 
transplantation. Multivariable Cox regression models were used to analyse the relationship 
between comorbidity and 2-year graft survival, patient survival and transplant survival (earliest of 
graft failure or patient death) for deceased-donor kidney transplant (DDKT) recipients (n=1288) 
and living-donor kidney transplant (LDKT) recipients (n=812).  
Results: For DDKT recipients, peripheral vascular disease (HR 3.04, 95%CI 1.37, 6.74, p=0.006) 
and obesity (HR 2.27, 95%CI 1.27, 4.06, p=0.006) were independent risk factors for graft loss, 
while heart failure (HR 3.77, 95%CI 1.79, 7.95, p=0.0005), cerebrovascular disease (HR 3.45, 
95%CI 1.72, 6.92, p=0.0005) and chronic liver disease (HR 4.36, 95%CI 1.29, 14.71, p=0.018) 
were associated with an increased risk of mortality. For LDKT recipients, heart failure (HR 3.83, 
95%CI 1.15, 12.81, p=0.029) and diabetes (HR 2.23, 95%CI 1.03, 4.81, p=0.042) were associated 
with poorer transplant survival. 
Conclusion: The key comorbidities that predict poorer 2-year survival outcomes after kidney 
transplantation have been identified in this large prospective cohort study. The findings will 
facilitate assessment of individual patient risks and evidence-based decision making. 
  AC
CE
PT
ED
5 
 
Introduction 
Kidney transplantation is widely regarded as the treatment of choice for end-stage renal disease 
(ESRD). However, outcomes after transplantation vary considerably between patients and 
prediction of individual risk is challenging due to the increasing prevalence of complex 
comorbidity among the ESRD population. Conditions such as diabetes, hypertension and obesity 
which contribute to the development of ESRD are on the rise,1 while ESRD itself is an important 
risk factor for other comorbidities such as cardiovascular disease.2, 3 Over the past decade, the 
proportion of deceased-donor kidney transplant (DDKT) recipients older than 60 years of age has 
increased from 17% to 29% in the UK,4 and the burden of comorbidity among patients 
undergoing kidney transplantation has also risen significantly.5-7 
Despite this, there are limited data on the impact of comorbidity on transplant outcomes. A small 
number of studies have demonstrated the overall detrimental effect of comorbidity on transplant 
outcomes using various comorbidity indices.5, 8-10 However, this does not allow characterisation 
of the risks associated with specific comorbid conditions.. Retrospective registry analyses have 
identified several comorbidities as risk factors for transplant outcomes, but the results show 
considerable heterogeneity and are limited by the reliability of the data.11-13 Up-to-date and 
reliable evidence is essential to enable clinicians to fully inform patients of their individual risks 
and likely outcomes, thereby facilitating shared decision-making and informed consent. 
We conducted a national prospective cohort study to investigate the impact of a wide range of 
baseline comorbid conditions on survival outcomes following kidney transplantation. We report 
the two-year survival outcomes of the study which was conducted as part of the Access to 
Transplantation and Transplant Outcome Measures (ATTOM) research programme.AC
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Materials and Methods 
Study design and participants 
ATTOM is a national prospective cohort study investigating the factors that influence access 
to and outcomes from renal transplantation in the UK. A full description of the ATTOM 
protocol has been reported previously.14 A cohort of 2262 incident kidney transplant 
recipients were recruited to ATTOM at the time of transplantation, from all 23 UK renal 
transplant centers. In each center recruitment took place over a 12-month period between 1st 
November 2011 and 31st March 2013. Patients aged 18-75 years were eligible for 
recruitment. For the purposes of this analysis, multi-organ transplant recipients (n=162) were 
excluded. The final study sample (n=2100) represented 73% of eligible study participants 
from the national kidney-only transplant population (Figure 1). Patients were followed up for 
two years from the date of transplant. DDKT recipients (n=1288) and living-donor kidney 
transplant (LDKT) recipients (n=812) were analysed separately.  
Data variables 
The variables of interest were recipient comorbidities at the time of transplantation 
comprising diabetes, ischaemic heart disease (IHD), heart failure (HF), atrial fibrillation, 
cardiac valve replacement, pacemaker, cerebrovascular disease (CVD), peripheral vascular 
disease (PVD), abdominal aortic aneurysm, chronic respiratory disease, chronic liver disease 
(CLD), blood borne viruses, malignancy, mental illness (definitions given in Table S1, SDC, 
http://links.lww.com/TP/B802) and body mass index (BMI).  
The primary outcome measures were graft survival, patient survival and transplant survival. 
Graft survival was defined as the time from transplantation to graft failure (earliest of return 
to dialysis or retransplantation), with censoring for death with a functioning graft, at last 
follow-up or at 2 years. Patient survival was defined as the time from transplantation to 
patient death, with censoring at last follow-up or at two years. Transplant survival is a 
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composite outcome defined as the time from transplantation to the earliest of graft failure or 
patient death, with censoring at last follow-up or at two years. 
Potential confounders considered in multivariable analyses included (a) recipient variables: 
age, gender, ethnicity, primary renal disease (as classified by ERA-EDTA codes15), time on 
dialysis, previous transplantation, sensitisation level, smoking status; (b) donor variables: age, 
gender, ethnicity, BMI; (c) transplant variables: human leukocyte antigen (HLA) mismatches 
(MM), cold ischaemia time (CIT), delayed graft function (DGF). Ethnicity was coded as 
White, Black, Asian and Other (including Chinese and mixed origin). Recipient calculated 
reaction frequency (cRF) ≥85% was used to define highly sensitised recipients. The cRF is 
the percentage of a pool of 10,000 UK donors to whom the recipient has unacceptable HLA 
antibodies. HLA mismatches were classified into 4 levels as defined by the current UK 
deceased-donor kidney allocation scheme: level 1 (000 HLA-A, B, DR MM), level 2 (0DR + 
0/1B MM), level 3 (0DR + 2B MM) or (1DR + 0/1B MM) and level 4 (1DR + 2B MM) or 
(2DR MM).16 
Data collection 
Baseline recipient variables (including comorbidity) were collected by trained research nurses 
at the time of transplantation from patient interviews, case notes, local electronic patient 
information systems and/or confirmed with the patient’s named consultant nephrologist. 
Independent validation of 5% of data entries in all research sites confirmed >98% 
concordance for all data fields.14 Donor and transplant variables and 2-year graft and patient 
survival data were obtained through linkage with the UK Transplant Registry. 
Statistical methods 
Baseline characteristics were compared with chi-squared tests for categorical data and Mann–
Whitney U tests for nonparametric continuous data. The impact of comorbidity on two-year 
survival outcomes was examined using Kaplan-Meier estimates and Cox proportional hazards 
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regression models. DDKT and LDKT recipients were analysed separately. As there were no 
significant differences in outcomes between recipients of donors after circulatory death and 
donors after brain death, all DDKT recipients were analysed together. For DDKT recipients, 
separate multivariable models were built for the three different outcomes of transplant, graft 
and patient survival. For LDKT recipients, modelling was only possible for transplant 
survival, as the lower number of graft failures and patient deaths prevented modelling of graft 
and patient survival separately. All comorbidities were considered for inclusion in the 
multivariable models, and those leading to a significant (p<0.05) change in log likelihood 
were retained using a manual backward elimination method. Models were adjusted for 
statistically significant variables as well as variables selected a priori on the basis of clinical 
relevance. Continuous variables were explored as linear, fractional polynomials and 
categorical variables. In all models, the effect of the time on dialysis variable was only found 
to be significant after 3 years, and thus it was converted to a binary variable (<3 years versus 
≥ 3 years) as this provided the best fit in each model. The relationship between recipient BMI 
and graft survival was also found to be better represented by converting BMI to a categorical 
variable, in accordance with the World Health Organisation (WHO) BMI classifications.17 
Potential interactions between all variables were tested, none were significant. The 
proportional hazards assumption was found to be satisfied for all variables after checking log 
cumulative hazards plots and Schoenfeld residuals. Frailty models were used to check for 
inter-center variation by using the likelihood ratio test to assess the change in -2LogL after 
inclusion of transplant center as a random effect. The adjusted risk difference (ARD) was 
calculated using methods described by Laubender et al.18 The ARD describes the absolute 
effect of the comorbidity risk factor on survival probabilities after adjustment for covariates 
in the multivariable model. Standard errors of the ARD were derived from bootstrap methods 
using 1000 resamples of the data. Patients with missing data were excluded, the extent of 
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missing data is shown in Table S2 (SDC, http://links.lww.com/TP/B802). Sensitivity 
analyses were conducted to test robustness of the results; each model was adjusted for a risk 
score developed from UK Transplant Registry data for kidney transplants performed in the 5 
years prior to the study recruitment period (2006 - 2011), rather than adjusting for individual 
confounding factors. This minimised the number of degrees of freedom in the models, and 
enabled checking for any missed comorbidity effects. All analyses were conducted using 
SAS® 9.4 (SAS Institute Inc, Cary, USA). 
Ethics approval 
East of England Research Ethics Committee (reference number 11/EE/0120). 
Results 
Baseline characteristics 
Characteristics of the DDKT (n=1288) and LDKT (n=812) recipients, donors and transplants 
are shown in Table 1. These were consistent with UK Transplant Registry data for the study 
recruitment period.19, 20 The demographics of recruited versus excluded patients were 
compared (Table S3, SDC, http://links.lww.com/TP/B802). There was a higher proportion of 
White patients in the recruited group compared with the excluded group, however there were 
no significant differences in age group, gender or type of transplant. Table 2 shows the 
prevalence of comorbidity in the study cohort at the time of transplantation. DDKT recipients 
had significantly higher rates of diabetes (16.0% vs 10.3%, p=0.0002), IHD (9.8% vs 7.0%, 
p=0.029), HF (3.1% vs 1.6%, p=0.033), CVD (5.8% vs 3.1%, p=0.004) and PVD (3.3% vs 
1.7%, p=0.027) compared with LDKT recipients. 
DDKT recipients 
  Transplant survival 
Overall, there were 134 “transplant failures” (85 graft failures and 49 patient deaths). The 
Kaplan-Meier estimate for two-year transplant survival was 89.4% (95% confidence interval 
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[CI] 87.6, 91.0). After adjustment for relevant factors in the multivariable Cox regression 
model, HF (HR 2.39, 95% CI 1.30, 4.37, p=0.005) and CVD (HR 2.33, 95% CI 1.40, 3.88, 
p=0.001) were associated with a significant increase in the risk of transplant failure (Table 3). 
There was no significant inter-center variation in transplant survival when including 
transplant center as a random effect in the model (difference in -2LogL=0.02, degrees of 
freedom [df]=1, p=0.885). For HF, the ARD was 0.117 (standard error [SE] 0.052) (i.e. 
patients with heart failure had an 11.7% increased risk of transplant failure within 2 years 
compared to those without heart failure, after adjustment for all other factors in the 
multivariable model). For CVD, the ARD was 0.101 (SE 0.043). The effect of adding DGF to 
the final model is shown in Table S4 (SDC, http://links.lww.com/TP/B802). 
a) Graft survival 
At two years, there were 85 graft failures, and the Kaplan-Meier estimate of graft survival 
was 93.2% (95% CI 91.7, 94.5). Multivariable Cox regression modelling showed PVD (HR 
3.04, 95% CI 1.37, 6.74, p=0.006) and obesity (BMI ≥30.0) (HR 2.27, 95% CI 1.27, 4.06, 
p=0.006, compared with normal BMI 18.5 – 24.9) to be independent risk factors for graft loss 
(Table 3). The obesity variable was explored further in the model by dividing it into class I 
and class II and above (BMI 30.0 – 34.9 and  ≥35.0 respectively) (Table S5, SDC, 
http://links.lww.com/TP/B802). There were too few patients with obesity class III (BMI 
≥40.0) (n=7) to include this as a separate category. There was no significant variation in the 
risk of graft failure for the different classes of obesity, therefore the broader category of 
obesity (BMI ≥30.0) was retained in the main model (Table 3). No center effect on graft 
survival was found when modelling center as a random effect (difference in -2LogL=0.23, 
df=1, p=0.632). Among patients with PVD, the risk of graft failure was highest in the first ten 
days following transplantation, as demonstrated by the initial steep drop in the survival curve 
before the more gradual decline (Figure 2A); 85.7% graft failures in the PVD group occurred 
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during this early postoperative period, compared with 26.9% among patients without PVD. In 
contrast, the impact of obesity on graft survival followed a more gradual decline over the 
two-year period (Figure 2B). Unadjusted two-year graft survival estimates for patients with 
and without PVD and obesity are shown in Table 4. The ARD for PVD was 0.104 (SE 0.058) 
and for obesity was 0.060 (SE 0.029). The incidence of delayed graft function was 31.1% for 
all patients, 48.7% for patients with PVD and 39.1% for patients with obesity. Adding DGF 
to the final model resulted in a reduction in the effect of PVD (Table S4, SDC, 
http://links.lww.com/TP/B802). The cause of graft failure for all patients as well as patients 
with PVD and obesity in the DDKT cohort is shown in Table 5.  
b) Patient survival 
There were 56 patient deaths, of which 49 were deaths with a functioning graft. The two-year 
Kaplan-Meier survival estimate was 95.4% (95% CI 94.1, 96.5). The comorbidities 
significantly associated with inferior patient survival in the multivariable model included HF 
(HR 3.77, 95% CI 1.79, 7.95, p=0.0005), CVD (HR 3.45, 95% CI 1.72, 6.92, p=0.0005) and 
CLD (HR 4.36, 95% CI 1.29, 14.71, p=0.018) (Table 3). There were no significant center 
differences in patient survival (difference in -2LogL=0.01, df=1, p=0.925). Among patients 
with HF and CVD, just over half of patient deaths occurred in the second year after 
transplantation (55.6% and 58.3% respectively), while 100% of deaths among patients with 
CLD occurred within the first year post transplantation. This is demonstrated by the survival 
curves in Figures 3A, 3B and 3C. Unadjusted 2-year patient survival estimates for patients 
with and without HF, CVD and CLD are shown in Table 6. For HF, CVD and CLD the ARD 
was 0.159 (SE 0.057), 0.041 (SE 0.027) and 0.056 (SE 0.091) respectively. The effect of 
adding DGF to the final model is shown in Table S4 (SDC, http://links.lww.com/TP/B802). 
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LDKT recipients 
In the LDKT cohort it was only possible to model transplant survival, as the smaller number 
of recipients and outcome events prevented meaningful analysis of separate graft and patient 
survival models. There were 42 “transplant failures” (26 graft failures and 16 patient deaths). 
The Kaplan-Meier estimate for transplant survival at 2 years was 94.7% (95% CI 92.9, 96.0). 
The multivariable model demonstrated significantly higher risk of transplant failure for HF 
(HR 3.83, 95% CI 1.15, 12.81, p=0.029) and diabetes (HR 2.23, 95% CI 1.03, 4.81, p=0.042) 
(Table 7). There was no significant center effect on LDKT transplant survival (difference in -
2LogL=0.11, df=1, p=0.741). The ARD for HF was 0.121 (SE 0.099) and for diabetes was 
0.056 (SE 0.036).  
Sensitivity analyses 
Each multivariable model was checked by adjusting for a risk score (Boxes S1, S2, S3 and 
S4) rather than entering the confounding factors individually into the model (Tables S6, S7, 
S8 and S9, SDC, http://links.lww.com/TP/B802). No additional comorbidities were identified 
as significant, and hazard ratios were very similar to the original models, confirming the 
reliability of the results. 
Discussion 
In this national observational study, we have collected data prospectively on a wide range of 
comorbid conditions and identified those that predict poorer survival outcomes after kidney 
transplantation. Among DDKT recipients, PVD and obesity were associated with a two- to 
three-fold increased risk of graft failure within two years of transplantation, while the risk of 
death was three- to four-fold higher with HF, CVD and CLD. For LDKT recipients, HF and 
diabetes were associated with significant detrimental effects on overall transplant survival, 
but longer follow up is required to determine the separate effects on graft and patient 
survival. 
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Among DDKT recipients, a history of PVD increased the risk of graft failure by 10.4% after 
adjusting for confounding factors, with the majority of graft failures occurring in the early 
postoperative period. PVD is typically diagnosed clinically by measuring the ankle-brachial 
pressure index (ABPI), and our results are in agreement with a US study of 819 patients 
which reported a 2.77 times increased risk of graft failure for patients with a low ABPI 
(<0.9).21 Preexisting PVD affecting the aorta or iliac arteries may complicate implantation of 
the kidney graft, resulting in difficult anastomoses, cholesterol emboli or hypoperfusion of 
the graft, and subsequent failure in the early postoperative period.22, 23 Our data showed a 
high incidence of technical operative issues as the cause of graft failure among PVD patients 
(42.9%). We also found that the addition of DGF to the regression model for DDKT graft 
survival reduced the effect of PVD and is thus a potential mediator of this effect. Despite 
being a high risk group, patients with PVD still derive a significant survival benefit from 
transplantation compared with dialysis.24, 25 As such, a history of PVD should not preclude 
transplantation, but given the high risk of early complications, appropriate preoperative 
planning and informed consent of patients is crucial. 
Obesity is an ongoing topic of controversy with regard to patient suitability for kidney 
transplantation. Some centers do not exclude patients with obesity, while others restrict 
access to the waiting list at specific BMI thresholds, which may differ considerably between 
centers, and even between clinicians within the same center.26 Despite conflicting outcomes 
from early single-center studies, more recent meta-analyses have confirmed the detrimental 
effect of obesity on graft survival.27-30 Our results are in keeping with this evidence; with 
obesity conferring a 6%  increased risk of graft failure among DDKT recipients. The 
mechanisms for this are unclear. There was a high incidence of acute rejection as a cause of 
graft failure among obese patients (44%) and this could be a potential cause for the higher 
risk of graft failure associated with obesity. Difficulties in achieving and maintaining the 
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narrow therapeutic target concentrations of immunosuppressive drugs in obese patients have 
previously been reported.31 
We found that HF was associated with a 15.9% higher risk of mortality after DDKT and 
12.1% higher risk of transplant failure after LDKT. We acknowledge that in patients on 
dialysis, it can be difficult to make a clear distinction between HF and fluid overload; 
however, our findings demonstrate that a diagnosis of heart failure in the patient’s record 
predicts poorer survival, irrespective of how the diagnosis was made or the exact 
pathophysiology. It is also noteworthy that although HF was identified as a significant risk 
factor, no effect was observed for IHD. Our findings concur with the results of a US study 
which found that pretransplant impaired left ventricular systolic function (on single photon 
emission computed tomography (SPECT)) was associated with a significantly higher risk of 
both cardiac mortality and all-cause mortality after kidney transplantation, while cardiac 
ischaemia (on SPECT) was not.32 Our findings suggest that either IHD does not increase the 
risk of death within two years post transplantation, or that current risk stratification of 
patients with IHD in the UK is effective. 
CVD was associated with a 4.1% elevated risk of death among DDKT recipients. It is known 
that patients with ESRD have more severe carotid atherosclerosis than the general population 
and are at substantially greater risk of stroke.33-35 A large US registry analysis demonstrated 
that transplantation reduced the risk of cerebrovascular events from 11.8% to 6.8% compared 
to patients remaining on the waiting list.36 However, previous CVD remains a strong risk 
factor for further post transplantation events and mortality.35, 37, 38 Post transplantation 
cerebrovascular events are associated with high mortality,39 which is worse for haemorrhagic 
strokes (48%) compared with ischaemic strokes (6%).38 In a prospective randomised 
controlled trial including 1652 kidney transplant recipients (ALERT trial), the use of 
Fluvastatin did not reduce the incidence of cerebrovascular events or mortality.38 Further 
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trials are needed to assess the ability of therapies to reduce the risk of further cerebrovascular 
events and mortality in this high risk population. 
CLD was independently associated with 5.6% increased risk of mortality within two years of 
DDKT. There is a paucity of published research regarding CLD in kidney transplant 
outcomes. Previous studies have focussed on the role of hepatitis B and C related liver 
disease as predictors of increased mortality after kidney transplantation.40-42 The present 
study is the first to demonstrate that CLD of any aetiology leads to reduced survival after 
DDKT. Further research is required to understand the underlying mechanisms. 
Interestingly, a diagnosis of diabetes was identified as a risk factor for transplant failure 
among LDKT recipients, but not for DDKT recipients. The reason for this finding is unclear. 
Diabetes is a well-recognised risk factor for mortality after transplantation, primarily due to 
elevated cardiovascular risk.43 It may be that this cardiovascular risk was actually accounted 
for by other comorbidity variables in the models for DDKT recipients, while in the LDKT 
cohort with a significantly lower prevalence of other comorbidities, diabetes may have served 
as more general marker of poorer outcomes. A recent large population cohort study in 
Australia and New Zealand demonstrated that patients with Type 2 diabetes had significantly 
poorer survival after kidney transplantation, with the highest risk being among younger 
patients under the age of 40 years.44 In our study the LDKT population was significantly 
younger than the DDKT population and this may explain why diabetes was a significant risk 
factor in this population. The 5.6% higher risk of transplant failure among patients with 
diabetes (and 12% higher risk for patients with heart failure discussed previously) must be 
given due consideration in the context of LDKT, given the potential implications for both the 
recipient as well as the live donor.  
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A major strength of the present study is that it is a prospective and comprehensive analysis of 
a large cohort of transplant recipients from all UK transplant centers. The cohort included a 
large proportion of the national adult transplant population with a minimal amount of missing 
data, which adds to the reliability of the study. There are a number of limitations to this study. 
First, for practical reasons we used relatively broad definitions for each comorbidity and were 
unable to distinguish between differing levels of severity or duration for each condition. All 
comorbidity data were collected at the time of transplantation when patients were recruited to 
the study. Therefore, we were unable to assess the progression or improvement of each 
condition after transplantation, and whether this impacted on outcomes. Secondly, it should 
be noted that the study population is largely of white ethnicity and thus conclusions with 
respect to other ethnic groups may be less certain. Thirdly, due to the favourable survival 
outcomes of LDKT recipients, we were only able to analyse the composite outcome of 
transplant survival in this cohort, as there were too few events for separate analysis of graft 
and patient survival. Transplant survival (also known as graft survival not censored for death) 
is a commonly analysed end-point in the transplant literature, as it demonstrates the overall 
success of a transplant.45, 46 However, in the DDKT analysis we found that this method 
masked the importance of several comorbidity risk factors that were found to be significant 
when analysing graft and patient survival separately. Therefore, it is important that we carry 
out separate graft and patient survival analyses in the LDKT cohort after longer follow-up 
time. Finally, the results from this study describe associations and no causation can be 
inferred. 
This study quantifies the risks associated with specific comorbid conditions in the context of 
kidney transplantation. The findings can be utilised in everyday clinical practice to fully 
inform patients of their individual risks and outcomes, to inform future wait-listing and 
AC
CE
PT
ED
17 
 
allocation policy and also to guide further research into improving the outcomes of patients 
with specific comorbidities. 
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Figures 
Figure 1. Study population and analyses. Patients were recruited from all 23 UK renal 
transplant centers. Recruitment took place over a 12-month period in each center, between 1st 
November 2011 and 31st March 2013 
Figure 2. Kaplan-Meier curves for 2-year graft survival of deceased-donor kidney transplants 
A. Peripheral vascular disease (PVD). B. Body mass index (BMI) 
Figure 3. Kaplan-Meier curves for 2-year patient survival after deceased-donor kidney 
transplantation 
A. Heart failure (HF). B. Cerebrovascular disease (CVD). C. Chronic liver disease (CLD) 
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Tables 
 
 
Table 1. Characteristics of the study cohort 
 DDKT recipients 
n=1288 
LDKT recipients 
n=812 
p-value 
Recipient variables    
Recipient age, years (median, IQR) 54 (44 - 63) 46 (34 - 56) <0.0001 
Recipient age group, years (n, %)   <0.0001 
18 – 34 132 (10.3) 229 (28.2)  
35 – 49 369 (28.7) 263 (32.4)  
50 – 64 543 (42.2) 252 (31.0)  
65 – 75 244 (18.9) 68 (8.4)  
Recipient gender (n, %)   0.267 
Male 824 (64.0) 500 (61.6)  
Female 464 (36.0) 312 (38.4)  
Recipient ethnicity (n, %)   0.0002 
White 1023 (79.7) 707 (87.1)  
Asian 140 (10.9) 62 (7.6)  
Black 96 (7.5) 35 (4.3)  
Other 25 (2.0) 8 (1.0)  
Primary renal disease (n, %)     <0.0001 
Polycystic kidney disease 219 (17.0) 112 (13.9)  
Diabetic nephropathy 134 (10.4) 48 (5.9)  
Glomerulonephritis 320 (24.9) 232 (28.7)  
Pyelonephritis 138 (10.7) 128 (15.8)  
Hypertensive nephropathy 89 (6.9) 37 (4.6)  
Renal vascular disease 29 (2.3) 9 (1.1)  
Other 163 (12.7) 85 (10.5)  
Uncertain 194 (15.1) 157 (19.4)  
Time on dialysis (n, %)     <0.0001 
Preemptive 137 (10.6) 279 (34.4)  
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0 - 1 year 160 (12.4) 198 (24.4)  
1 - 3 years 366 (28.4) 185 (22.8)  
3 - 5 years 295 (22.9) 78 (9.6)  
> 5 years 330 (25.6) 72 (8.9)  
Previous transplant (n, %) 165 (12.9) 117 (14.5) 0.297 
Highly sensitised, cRF≥85% (n, %) 126 (9.8) 95 (11.7) 0.163 
Smoking status (n, %)   0.702 
Nonsmoker 137 (11.7) 78 (10.7)  
Ex-smoker 325 (27.7) 212 (29.2)  
Smoker 710 (60.6) 437 (60.1)  
Donor variables    
Donor age, years (median, IQR) 54 (43 - 64) 48 (39 - 57) <0.0001 
Donor age group, years (n, %)   <0.0001 
<18 31 (2.4) 0  
18 – 34 160 (12.4) 143 (17.6)  
35 – 49 303 (23.5) 298 (36.7)  
50 – 64 512 (39.8) 308 (37.9)  
65 – 75 234 (18.2) 61 (7.5)  
>75 48 (3.7) 2 (0.3)  
Donor gender (n, %)   0.001 
Male 696 (54.0) 379 (46.7)  
Female 592 (46.0) 432 (53.3)  
Donor ethnicity (n, %)   <0.0001 
White 1208 (95.2) 720 (88.7)  
Asian 21 (1.7) 52 (6.4)  
Black 23 (1.8) 28 (3.5)  
Other 17 (1.3) 12 (1.5)  
Donor BMI, kg/m2 (n, %)   <0.0001 
Underweight (<18.5) 0 0  
Normal (18.5 - 24.9) 463 (37.3) 254 (32.9)  
Overweight (25.0 - 29.9) 494 (39.7) 390 (50.5)  
Obese (≥30.0) 286 (23.0) 128 (16.6)  
Transplant variables    
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HLA MM level (n, %)   <0.0001 
1 155 (12.0) 91 (11.2)  
2 355 (27.6) 105 (12.9)  
3 679 (52.7) 360 (44.3)  
4 99 (7.7) 256 (31.5)  
CIT, hours (median, IQR) 14.5 (11.4 - 17.3) 3.3 (2.4 - 4.1) <0.0001 
Delayed graft function (n, %) 378 (31.1) 30 (3.9) <0.0001 
DDKT; deceased-donor kidney transplant, LDKT; living-donor kidney 
transplant, IQR; interquartile range, cRF; calculated reaction frequency, BMI; 
body mass index, HLA MM; human leukocyte antigen mismatch, CIT; cold 
ischaemia time. Data are missing for some participants and excluded from 
percentage calculations. Number of missing data are shown in Table S2 (SDC, 
http://links.lww.com/TP/B802). 
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Table 2. Prevalence of recipient comorbidity 
 DDKT recipients 
n=1288 
LDKT recipients 
n=812 
p-value 
Diabetes (n, %) 205 (16.0) 83 (10.3) 0.0002 
Ischaemic heart disease (n, %) 126 (9.8) 57 (7.0) 0.029 
Heart failure (n, %) 40 (3.1) 13 (1.6) 0.033 
Atrial fibrillation (n, %) 25 (1.9) 12 (1.5) 0.434 
Cardiac valve replacement (n, %) 10 (0.8) 8 (1.0) 0.609 
Pacemaker (n, %) 10 (0.8) 5 (0.6) 0.673 
Cerebrovascular disease (n, %) 75 (5.8) 25 (3.1) 0.004 
Peripheral vascular disease (n, %) 43 (3.3) 14 (1.7) 0.027 
Abdominal aortic aneurysm (n, %) 4 (0.3) 2 (0.3) 0.790 
Chronic respiratory disease (n, %) 108 (8.4) 59 (7.3) 0.359 
Chronic liver disease (n, %) 25 (1.9) 14 (1.7) 0.722 
Blood borne viruses (n, %) 38 (3.0) 13 (1.6) 0.051 
Malignancy (n, %) 93 (7.2) 49 (6.1) 0.294 
Mental illness (n, %) 75 (5.8) 41 (5.1) 0.453 
BMI, kg/m2 (n, %)   0.121 
Underweight (<18.5) 26 (2.1) 23 (3.0)  
Normal (18.5 - 24.9) 461 (37.5) 312 (40.8)  
Overweight (25.0 - 29.9) 462 (37.6) 282 (36.9)  
Obese (≥30.0) 281 (22.9) 147 (19.2)  
Number of comorbidities (n, %)   0.002 
0 573 (46.7) 414 (54.4)  
1 - 2 579 (47.2) 316 (41.5)  
≥3 74 (6.0) 31 (4.1)  
DDKT; deceased-donor kidney transplant, LDKT; living-donor kidney 
transplant, BMI; body mass index. Data are missing for some participants and 
excluded from percentage calculations. Number of missing data are shown in 
Table S2. 
AC
CE
PT
ED
29 
 
Table 3. Cox regression analysis for impact of comorbidity on 2-year survival outcomes of deceased donor kidney transplants 
 Transplant survival model Graft survival model Patient survival model 
Variables HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Recipient comorbidity       
Heart failure 2.39 (1.30, 4.37) 0.005 - - 3.77 (1.79, 7.95) 0.0005 
Cerebrovascular disease 2.33 (1.40, 3.88) 0.001 - - 3.45 (1.72, 6.92) 0.0005 
Chronic liver disease - - - - 4.36 (1.29, 14.71) 0.018 
Peripheral vascular disease - - 3.04 (1.37, 6.74) 0.006 - - 
BMI, kg/m2       
Underweight (<18.5) - - 0.86 (0.11, 6.49) 0.885 - - 
Normal (18.5 - 24.9) - - 1 (reference)  - - 
Overweight (25.0 - 29.9) - - 1.48 (0.84, 2.61) 0.180 - - 
Obese (≥30.0) - - 2.27 (1.27, 4.06) 0.006 - - 
Other variables       
Time on dialysis (years)       
< 3 1 (reference)  1 (reference)  1 (reference)  
≥ 3 2.08 (1.41, 3.08) 0.0002 1.84 (1.11, 3.04) 0.018 2.47 (1.36, 4.50) 0.003 
Recipient age (per 10 years) 1.10 (0.92, 1.30) 0.290 0.84 (0.68, 1.05) 0.128 1.67 (1.23, 2.25) 0.0009 
Recipient ethnicity       
White 1 (reference)  1 (reference)  - - 
Asian 0.67 (0.35, 1.29) 0.228 0.76 (0.35, 1.69) 0.504 - - 
Black 1.23 (0.68, 2.21) 0.495 1.52 (0.77, 3.02) 0.228 - - 
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Other 0.37 (0.05, 2.63) 0.317 0.62 (0.08, 4.53) 0.636 - - 
Highly sensitised (cRF≥85%) 1.47 (0.87, 2.47) 0.153 2.22 (1.18, 4.19) 0.014 - - 
Donor age (per 10 years) 1.14 (0.99, 1.31) 0.066 1.23 (1.02, 1.48) 0.028 1.11 (0.89, 1.39) 0.349 
HLA MM level       
1 1 (reference)  1 (reference)  1 (reference)  
2 1.18 (0.62, 2.27) 0.612 2.94 (1.08, 7.98) 0.035 0.40 (0.16, 1.01) 0.052 
3 1.05 (0.57, 1.94) 0.866 2.25 (0.85, 5.93) 0.103 0.46 (0.21, 1.01) 0.051 
4 1.25 (0.53, 2.93) 0.612 2.78 (0.81, 9.59) 0.106 0.66 (0.22, 2.01) 0.467 
Cold ischaemia time (per hour) 1.04 (1.01, 1.08) 0.028 1.01 (0.97, 1.06) 0.568 1.04 (0.99, 1.10) 0.118 
HR; hazard ratio, CI; confidence interval, BMI; body mass index, cRF; calculated reaction frequency, HLA MM; human leukocyte antigen mismatch.  
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Table 4. Kaplan-Meier estimates for 2-year graft survival of 
deceased-donor kidney transplants 
Comorbidity Survival (95% CI)  p-value 
Peripheral vascular disease  0.006 
No 93.6 (92.0, 94.8)  
Yes 83.5 (68.5, 91.8)  
BMI, kg/m2  0.012 
Normal (18.5 - 24.9) 95.2 (92.7, 96.8)  
Obese (≥30.0) 90.1 (85.9, 93.1)  
p-value is for log-rank test. 
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Table 5. Cause of graft failure among DDKT cohort 
Cause of graft failure All patients Obese patients PVD patients 
Acute rejection 26 (34.2%) 11 (44.0%) 1 (14.3%) 
Vascular thrombosis 6 (7.9%) 0 (0%) 1 (14.3%) 
Technical operative issues 9 (11.8%) 3 (12.0%) 3 (42.9%) 
Nonviable kidney 9 (11.8%) 3 (12.0%) 1 (14.3%) 
Infection 1 (1.3%) 0 (0%) 0 (0%) 
Recurrent primary renal disease 4 (5.3%) 0 (0%) 0 (0%) 
Other 21 (27.6%) 8 (32.0%) 1 (14.3%) 
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Table 6. Kaplan-Meier estimates for 2-year patient survival after 
deceased-donor kidney transplantation 
Comorbidity Survival (95% CI)  p-value 
Heart failure  <0.0001 
No 96.0 (94.8, 97.0)  
Yes 75.8 (58.5, 86.7)  
Cerebrovascular disease  <0.0001 
No 96.2 (94.9, 97.1)  
Yes 82.7 (71.5, 89.8)  
Chronic liver disease  0.003 
No 95.7 (94.3, 96.7)  
Yes 83.6 (62.0, 93.5)  
p-value is for log-rank test. 
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Table 7. Cox regression analysis for impact of comorbidity on 2-
year transplant survival of living-donor kidney transplants 
Variables HR (95% CI) p-value 
Recipient comorbidity   
Heart failure 3.83 (1.15, 12.81) 0.029 
Diabetes 2.23 (1.03, 4.81) 0.042 
Other variables   
Time on dialysis (years)   
< 3 1 (reference)  
≥ 3 2.16 (1.13, 4.11) 0.019 
Recipient age (per 10 years) 1.01 (0.80, 1.28) 0.926 
Donor age (per 10 years) 1.03 (0.81, 1.31) 0.828 
HLA MM level   
1 1 (reference)  
2 0.76 (0.23, 2.51) 0.657 
3 0.74 (0.29, 1.86) 0.520 
4 0.67 (0.25, 1.82) 0.428 
HR; hazard ratio, CI; confidence interval, HLA MM; human 
leukocyte antigen mismatch. 
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Figure 2A 
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Figure 3C 
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